Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 25, Issue 34, Pages 5120-5133Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v25.i34.5120
Keywords
Allyl isothiocyanate; Nonalcoholic fatty liver disease; Hepatic steatosis; Liver inflammation
Categories
Funding
- Natural Science Foundation of China [81700504, 81700511]
- Science Foundation of Health Bureau of Zhejiang Province [2017183691]
- Natural Science Foundation of Zhejiang Province [LY17H030006, LQ15H030002]
- Zhejiang Medical Science and Technology Project [2017193668]
Ask authors/readers for more resources
BACKGROUND Allyl isothiocyanate (AITC), a classic anti-inflammatory and antitumorigenic agent, was recently identified as a potential treatment for obesity and insulin resistance. However, little is known about its direct impact on the liver. AIM To investigate the effect and underlying mechanism of AITC in nonalcoholic fatty liver disease (commonly referred to as NAFLD). METHODS To establish a mouse and cellular model of NAFLD, C57BL/6 mice were fed a high fat diet (HFD) for 8 wk, and AML-12 cells were treated with 200 mu M palmitate acid for 24 h. For AITC treatment, mice were administered AITC (100 mg/kg/d) orally and AML-12 cells were treated with AITC (20 mu mol/L). RESULTS AITC significantly ameliorated HFD-induced weight gain, hepatic lipid accumulation and inflammation in vivo. Furthermore, serum alanine aminotransferase and aspartate aminotransferase levels were markedly reduced in AITC-treated mice. Mechanistically, AITC significantly downregulated the protein levels of sterol regulatory element binding protein 1 (SREBP1) and its lipogenesis target genes and upregulated the levels of proteins involved in fatty acid beta-oxidation, as well as the upstream mediators Sirtuin 1 (Sirt1) and AMP-activated protein kinase alpha (AMPK alpha), in the livers of HFD-fed mice. AITC also attenuated the nuclear factor kappa B (NF-kappa B) signaling pathway. Consistently, AITC relieved palmitate acid-induced lipid accumulation and inflammation in AML-12 cells in vitro through the Sirt1/AMPK and NF-kappa B signaling pathways. Importantly, further studies showed that the curative effect of AITC on lipid accumulation was abolished by siRNA-mediated knockdown of either Sirt1 or AMPKa in AML-12 cells. CONCLUSION AITC significantly ameliorates hepatic steatosis and inflammation by activating the Sirt1/AMPK pathway and inhibiting the NF-kappa B pathway. Therefore, AITC is a potential therapeutic agent for NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available